Myocardial infarction mortality risk after treatment for hodgkin disease: A collaborative British cohort study

Journal of the National Cancer Institute

Volumn 99, Issue 3, 2007, Pages 206-214

  Swerdlow, Anthony J ^a   Higgins, Craig D ^a   Smith, Paul ^g   Cunningham, David ^b   Hancock, Barry W ^c   Horwich, Alan ^a   Hoskin, Peter J ^d   Lister, Andrew ^e   Radford, John A ^f   Rohatiner, Ama Z S ^e   Linch, David C ^g  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEART DEATH; HEART INFARCTION; HODGKIN DISEASE; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION HAZARD; RISK ASSESSMENT; SIDE EFFECT; UNITED KINGDOM; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FOLLOW UP; HEART; METHODOLOGY; MIDDLE AGED; MORTALITY; RADIATION EXPOSURE; RADIATION INJURY; REGISTER; RISK FACTOR; TIME;

ADULT; AGE FACTORS; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEART; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; REGISTRIES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VINCRISTINE;

EID: 33847760275     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk029     Document Type: Article

References (19)

1. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, van'tVeer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431-9.
2. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997;8 Suppl 1:115-8.
3. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002;20:2101-8.
4. Swerdlow AJ, van Leeuwen FE. Late effects after treatment for Hodgkin lymphoma. In: Degos L, Linch DC, Lowenberg B, editors. Textbook of malignant hematology. 2nd ed. London(U.K.): Taylor & Francis; 2005. p. 753-68.
5. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993;11:1208-15.
6. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. J Am Med Assoc 1993;270:1949-55.
7. Boivin J-F, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992;69:1241-7.
8. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263-302.
9. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. 9th rev. Vol 1. Geneva(Switzerland): World Health Organization; 1977.
10. Breslow NE, Day NE. Statistical methods in cancer research. Volume II-the design and analysis of cohort studies. IARC Scientific Publication No. 82. Lyon(France): International Agency for Research on Cancer; 1987.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
12. McKinlay S, Jefferys M, Thompson B. An investigation of the age at menopause. J Biosoc Sci 1972;4:161-73.
13. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. J Am Med Assoc 2003;290:2831-7.
14. Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22:3139-48.
15. Moreb JS, Obion DJ. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer 1992;70:2637-41.
16. Avilés A, Neri N, Nambo MJ, Huerta-Guzman J, Talavera A, Cleto S. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 2005;46:1023-8.
17. Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006;107:2912-9.
18. Mandel EM, Lewinski U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer 1975;36:1979-82.
19. Somers G, Abramow M, Wittek M, Naets JP. Myocardial infarction: a complication of vincristine treatment?. Lancet 1976;2:690.